THE JENEX CORPORATION

PRIVATE PLACEMENT

FOR IMMEDIATE RELEASE

March 15, 2003

Burlington, Ontario

Burlington, Ontario - THE JENEX CORPORATION ("Jenex" or the "Corporation") (TSX Venture Exchange – “JEN”), has arranged a non-brokered expedited private placement to issue 304,498 units at a purchase price of 25.5 cents per unit, to qualifying residents under applicable securities legislation, for gross proceeds of $77,647. Each unit will consist of one common share and one common share purchase warrant. Each full warrant entitles the holder to purchase one additional common share of the corporation at a purchase price of 40 cents per common share, on or before that day which is the earlier of 12 months from the closing of the sale of units or any 10-day period immediately following a period where the corporation's common shares have traded at a weighted daily average price greater than or equal to 80 cents for 10 consecutive trading days and the average daily trading volume exceeds 5,000 common shares per day. Additional details concerning conversion rights will be contained in the warrant certificates issued on closing.

The transaction is subject to customary regulatory approval and all common shares and underlying securities will be subject to a standard four-month hold period. The proceeds from the private placement will be used to complete the development of the corporation's cold sore prevention device and prepare for the Canadian launch in late 2004.